Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 20Carcinoma, Non-Small-Cell Lung 20Carcinoma, Hepatocellular 15Brain Neoplasms 12Breast Neoplasms 10Pancreatic Neoplasms 9Neoplasm Metastasis 9Lung Neoplasms 5Neoplasms 4Recurrence 3Colorectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neuroma, Acoustic 2NSCLC 2Liver Neoplasms 2Head and Neck Neoplasms 2Glioblastoma 2Esophageal Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer 1Stage IA - IB Non Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Spine Metastasis 1Spinal Neoplasms 1Spinal Bone Metastases 1Solid Tumor 1Sarcoma 1Rare Diseases 1Radiotherapy 1

Interventions

irinotecan sucrosofate 1folfirinox 1Taxes 1Surgical Procedures, Operative 1Radiotherapy 1Radiosurgery 1Oxaliplatin 1Leucovorin 1Gemcitabine 1Folfox protocol 1Fluorouracil 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Pancreatic Adenocarcinoma × Radiosurgery × Clear all
NCT05181605 2022-08-09

Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors

Instituto de investigación e innovación biomédica de Cádiz

Phase 2/3 Unknown
116 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡